TP53 and prostate carcinoma: Therefore, prostate cancer cell lines like LNCaP (AR-positive) and PC-3 (AR-negative) may have evolved/adapted gene expression programs, through AR-mutation or p53-mutation, to escape the growth suppressive actions of androgens [39,75–77].